Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration.

Sci Rep · 2024 · PMC11208512 · PMID 38926553

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although there was no significant difference in the changes in the BCVA and CRT from the baseline at all study visits, the SCD411 group showed a trend towards better BCVA and CRT changes at the end of the follow-up.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.